An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 8, 2005, Pages 1704-1710

  Devlin, Cecilia M ^a   Lee, Sung Joon ^b,c   Kuriakose, George ^a   Spencer, Craig ^e   Becker, Lev ^e   Grosskopf, Itamar ^c   Ko, Carol ^a   Huang, Li Shin ^a   Koschinsky, Marlys L ^e   Cooper, Allen D ^c,d   Tabas, Ira ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Korea University   (South Korea)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PALO ALTO MEDICAL FOUNDATION   (United States)

^e QUEEN S UNIVERSITY   (Canada)

Author keywords

Apolipoprotein(a); Atherosclerosis; Hepatic clearance; Lipoprotein(a); Remnant lipoproteins

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; CHYLOMICRON; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CELL INTERACTION; CELL SPECIFICITY; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; IN VIVO STUDY; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER CLEARANCE; MALE; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY MECHANISM; RISK ASSESSMENT; TRANSGENIC MOUSE;

ANIMALS; AORTA; APOLIPOPROTEIN B-100; APOLIPOPROTEIN B-48; APOLIPOPROTEINS A; APOLIPOPROTEINS B; ATHEROSCLEROSIS; CHOLESTEROL; CHOLESTEROL, VLDL; CHYLOMICRON REMNANTS; CHYLOMICRONS; FEMALE; HUMANS; KRINGLES; LIPOPROTEINS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RATS; TRIGLYCERIDES;

EID: 23244466662     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000170819.57945.03     Document Type: Article

References (34)

1. Scanu AM, Fless GM. Lipoprotein(a). Heterogeneity and biological relevance. J Clin Invest. 1990;85:1709-1715.
2. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246:904-910.
3. Gaubatz JW, Hoogeveen RC, Hoffman AS, Ghazzaly KG, Pownall HJ, Guevara J Jr, Koschinsky ML, Morrisett JD. Isolation, quantitation, and characterization of a stable complex formed by Lp[a] binding to triglyceride-rich lipoproteins. J Lipid Res. 2001;42:2058-2068.
4. Bersot TP, Innerarity TL, Pitas RE, Rall SC Jr, Weisgraber KH, Mahley RW. Fat feeding in humans induces lipoproteins of density less than 1.006 that are enriched in apolipoprotein [a] and that cause lipid accumulation in macrophages. J Clin Invest. 1986;77:622-630.
5. Bard JM, Delattre-Lestavel S, Clavey V, Pont P, Derudas B, Parra HJ, Fruchart JC. Isolation and characterization of two sub-species of Lp(a), one containing apo E and one free of apo E. Biochim Biophys Acta. 1992;1127:124-130.
6. McLean JW, Tomlinson JE, Kuang W, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132-137.
7. Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998;82:57U-66U.
8. Scanu AM. The role of lipoprotein(a) in the pathogenesis of atherosclerotic cardiovascular disease and its utility as predictor of coronary heart disease events. Curr Cardiol Rep. 2001;3:385-390.
9. Marcovina SM, Koschinsky ML. Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol. 2003;14:361-366.
10. Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol. 2004;15:167-174.
11. Scanu AM. Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications. Curr Atheroscler Rep. 2003;5:106-113.
12. Bottalico LA, Keesler GA, Fless GM, Tabas I. Cholesterol loading of macrophages leads to marked enhancement of native lipoprotein(a) and apoprotein(a) internalization and degradation. J Biol Chem. 1993;268:8569-8573.
13. Keesler GA, Li Y, Skiba PJ, Fless GM, Tabas I. Macrophage foam cell lipoprotein(a)/apoprotein(a) receptor. Cell-surface localization, dependence of induction on new protein synthesis, and ligand specificity. Arterioscler Thromb. 1994;14:1337-1345.
14. Keesler GA, Gabel BR, Devlin CM, Koschinsky ML, Tabas I. The binding activity of the macrophage lipoprotein(a)/apolipoprotein(a) receptor is up-regulated by cholesterol via a post-translational mechanism and recognizes distinct kringle domains on apolipoprotein(a). J Biol Chem. 1996;271:32096- 32104.
15. Skiba PJ, Keesler GA, Tabas I. Interferon-gamma down-regulates the lipoprotein(a)/apoprotein(a) receptor activity on macrophage loam cells. J Biol Chem. 1994;269:23059-23067.
16. Edelstein C, Italia JA, Klezovitch O, Scanu AM. Functional and metabolic differences between elastase-generated fragments of human lipoprotein[a] and apolipoprotein[a]. J Lipid Res. 1996;37:1786-1801.
17. Formato M, Farina M, Spirito R, Maggioni M, Guarino A, Cherchi GM, Biglioli P, Edelstein C, Scanu AM. Evidence for a proinflammatory and proteolytic environment in plaques from endarterectomy segments of human carotid arteries. Arterioscler Thromb Vasc Biol. 2004;24:129-135.
18. Boonmark NW, Lou XJ, Yang ZJ, Schwartz K, Zhang JL, Rubin EM, Lawn RM. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J Clin Invest. 1997;100:558-564.
19. Fan J, Sun H, Unoki H, Shiomi M, Watanabe T. Enhanced atherosclerosis in Lp(a) WHHL transgenic rabbits. Ann N Y Acad Sci. 2001;947:362-365.
20. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270:2195-2199.
21. Chiesa G, Hobbs HH, Koschinsky ML, Lawn RM, Maika SD, Hammer RE. Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a). J Biol Chem. 1992;267:24369-24374.
22. Schneider M, Witztum JL, Young SG, Ludwig EH, Miller ER, Tsimikas S, Curtiss LK, Marcovina SM, Taylor JM, Lawn RM, Innerarity TL, Pitas RE. High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. J Lipid Res. 2005;46:769-778.
23. Fortunato JE, Bassiouny HS, Song RH, Kocharian H, Glagov S, Edelstein C, Scanu AM. Apolipoprotein (a) fragments in relation to human carotid plaque instability. J Vasc Surg. 2000;32:555-563.
24. Hoppichler F, Kraft HG, Sandholzer C, Lechleitner M, Patsch JR, Utermann G. Lipoprotein(a) is increased in triglyceride-rich lipoproteins in men with coronary heart disease, but does not change acutely following oral fat ingestion. Atherosclerosis. 1996;122:127-134.
25. Song J, Hong SH, Min W, Kim JQ. Association between triglyceride-rich lipoprotein remnant receptor polymorphisms and lipid traits. Clin Biochem. 2000;33:441-447.
26. Argraves KM, Kozarsky KF, Fallon JT, Harpel PC, Strickland DK. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest. 1997;100:2170-2181.
27. Marz W, Beckmann A, Scharnagl H, Siekmeier R, Mondorf U, Held I, Schneider W, Preissner KT, Curtiss LK, Gross W. Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. FEBS Lett. 1993;325:271-275.
28. Ikewaki K, Cain W, Thomas F, Shamburek R, Zech LA, Usher D, Brewer HB Jr, Rader DJ. Abnormal in vivo metabolism of apoB-containing lipoproteins in human apoE deficiency. J Lipid Res. 2004;45:1302-1311.
29. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60:473-485.
30. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 1994;106:83-97.
31. Sposito AC, Ventura LI, Vinagre CG, Lemos PA, Quintella E, Santos RD, Carneiro O, Ramires JA, Maranhao RC. Delayed intravascular catabolism of chylomicron-like emulsions is an independent predictor of coronary artery disease. Atherosclerosis. 2004;176:397-403.
32. Wilhelm MG, Cooper AD. Induction of atherosclerosis by human chylomicron remnants: a hypothesis. J Atheroscler Thromb. 2003;10:132-139.
33. Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res. 1999;40:1-16.
34. Yu KC, Cooper AD. Postprandial lipoproteins and atherosclerosis. Front Biosci. 2001;6:D332-D354.